A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Lerouge, Delphine ^a   Rivière, Alain ^a   Dansin, Eric ^b   Chouaid, Christos ^c   Dujon, Cécile ^d   Schott, Roland ^e   Lavole, Armelle ^f   Le Pennec, Vincent ^g   Fabre, Elizabeth ^h   Crequit, Jacky ⁱ   Martin, Francis ^j   Dehette, Stéphanie ^j   Fournel, Pierre ^k   Precheur Agulhon, Bénédicte ^l   Lartigau, Eric ^b   Zalcman, Gérard ^g  

^a CRLCC Baclesse   (France)

^b Centre O Lambret   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^d CENTRE HOSPITALIER DE VERSAILLES   (France)

^e Department of Oncological Surgery   (France)

^f HÔPITAL TENON   (France)

^g CAEN UNIVERSITY HOSPITAL   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ Centre Hospitalier de Creil   (France)

^j Centre Hospitalier Compiegne   (France)

^k Cancer Institute Lucien Neuwirth   (France)

^l INSTITUT DE RECHERCHE PIERRE FABRE   (France)

more..

Author keywords

Chemoradiotherapy; Locally advanced non small cell lung cancer; Oral vinorelbine

Indexed keywords

CISPLATIN; NAVELBINE; ANTINEOPLASTIC AGENT; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LUNG INJURY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION INJURY; SURVIVAL RATE; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SURVIVAL RATE; VINBLASTINE;

EID: 84897948263     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-231     Document Type: Article

References (23)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917. 10.1002/ijc.25516, 21351269.
2. INCa 2010 La situation du cancer en France en 2010 Collection Rapports & Synthèses Ed. INC 2010, Paris, INCa 2010 La situation du cancer en France en 2010.
3. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005, 23(14):3175-3185. 10.1200/JCO.2005.10.462, 15886304.
4. Crino L, Weder W, van Meerbeeck J, Felip E. ESMO guidelines working group. Ann Oncol 2010, 21(suppl5):v103-v115.
5. Robinson LA, Ruckdeschel JC, Wagner H, Stevens CW. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(3 Suppl):243S-265S.
6. Summary of the Product Characteristics (Vinorelbine) 2012,
7. Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 2008, 62(1):85-91. 10.1016/j.lungcan.2008.02.009, 18372075.
8. Tan EH, Rolski J, Grodzki T, Schneider CP, Gatzemeier U, Zatloukal P, Aitini E, Carteni G, Riska H, Tsai YH, Abratt R. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2009, 20(7):1249-1256. 10.1093/annonc/mdn774, 19276396.
9. Vokes EE, Herndon JE, Crawford J, Leopold KA, Neill H, Perry MC, Miller AA, Green MR. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002, 20(20):4191-4198. 10.1200/JCO.2002.03.054, 12377962.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216. 10.1093/jnci/92.3.205, 10655437.
11. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38(1):143-151. 10.2307/2530297, 7082756.
12. Roswit B, Patno ME, Rapp R, Veinbergs A, Feder B, Stuhlbarg J, Reid CB. The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiology 1968, 90(4):688-697.
13. Rolland E, Le Chevalier T, Auperin A, Burdett S, Pignon JP. Sequential radio-chemotherapy (RT-CT) versus radiotherapy alone (RT) and concomitant RT-CT versus RT alone in locally advanced NSCLC: two meta-analyses using individual patient data (IPD) from randomised clinical trials (RCTs). J Thorac Oncol 2007, 2(Suppl 8):309-310.
14. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991, 83(6):417-423. 10.1093/jnci/83.6.417, 1847977.
15. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999, 17(9):2692-2699.
16. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(13):2181-2190. 10.1200/JCO.2009.26.2543, 20351327.
17. Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A, Delhoume JY, Le Treut J, Silvani JA, Dansin E, Bozonnat MC, Daurés JP, Mornex F, Pérol M. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005, 23(25):5910-5917. 10.1200/JCO.2005.03.070, 16087956.
18. Vergnenegre A, Daniel C, Lena H, Fournel P, Kleisbauer JP, Le Caer H, Letreut J, Paillotin D, Perol M, Bouchaert E, Preux PM, Robinet G. Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC). Lung Cancer 2005, 47(3):395-404. 10.1016/j.lungcan.2004.08.010, 15713523.
19. Horinouchi H, Sekine I, Sumi M, Noda K, Goto K, Mori K, Tamura T. Long term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer. Cancer Sci 2013, 104:93-97. 10.1111/cas.12028, 23004347.
20. Krzakowski M, Provencio M, Utracka-Hutka B, Villa E, Codes M, Kuten A, Henke M, Lopez M, Bell D, Biti G, Caux NR, Pouget JC, Dubray B, David P. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial. J Thorac Oncol 2008, 3(9):994-1002. 10.1097/JTO.0b013e31818396cb, 18758302.
21. Descourt R, Vergnenegre A, Barlesi F, Lena H, Fournel P, Falchero L, Berard H, Hureaux J, Le Caer H, Chavaillon JM, Geriniere L, Monnet I, Chouabe S, Robinet G. Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study. J Thorac Oncol 2011, 6(2):351-357. 10.1097/JTO.0b013e318200f47e, 21164367.
22. Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W, Richards D, Bruetman D, Anderson T, Chowhan N, Nattam S, Mantravadi P, Johnson C, Breen T, White A, Einhorn L. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008, 26(35):5755-5760. 10.1200/JCO.2008.17.7840, 19001323.
23. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008, 26(15):2450-2456. 10.1200/JCO.2007.14.4824, 18378568.